



Your One-Stop Shop to Asian Biotech Innovations

Q2 2026

Travel Together, Go The Distance

We are the “Only-In-Class” in the East-West Biotech Collaboration Space

- East-West pharmaceutical licensing transactions and R&D collaborations are exploding!
- The vast Asian biotech membership from [InScienceWeTrust Community](#) provides a large, high-quality East-West biotech space.
- [ISWT BioAdvisory](#), [Mianus Accelerator](#), and [IntelliPro](#) together create a **One-Stop Shop** to Asian biotech innovations.
- Our team has impressive track records in the East-West **BD&L and R&D collaboration**.



Visit us at www.iswtb.com

Our team has ~140 years of combined industry experiences



Leon Tang, MS, PhD
Founding Partner



Jimmy Ren, PhD
Senior Advisor



Michael An, MD/PhD
Senior Advisor



Oriana Zinani, PhD
Principal



Wenjun Sun, MS, MBA
Partner At Large



Steve Yang, MBA
Strategic Partner



ISWTB team members have impressive deal-making records

J&J paid **\$350 million upfront** for BCMA-CAR-T from **Legend Biotech**
[2017](#)

J&J paid **\$245 million upfront** for two CAR-Ts from **CBMG**
[2023](#)

VelaVigo out-licensed preclinical ADC to **Avenzo Tx** in a \$750-M deal with **\$50M upfront**
[2024](#)

JW Therapeutics in-licensed cell therapy technology from **Lyell Immunopharma**
[2020](#)

J&J formed an ADC R&D partnership with **Hanzhou DAC Group**
[2022](#)

Henlius out-licensed two biosimilars to **Organon** for \$73 million upfront
[2022](#)

Merck & Co formed a JV with **Simcere** to market cardiovascular assets in China
[2011](#)

JW Therapeutics in-licensed clinical stage CD19 CAR-T from **Juno Tx** for China
[2016](#)

Henlius in-licensed a Phase 1 BRAFi from **NeuPharma**
[2021](#)

Henlius in-licensed a first-in-class IO asset from **Palleon Pharma**
[2022](#)

- ISWTB team members have contributed to **13 publicly disclosed deals**.
- All the deals amount to at least **\$723 million upfront payments** and **\$billions of total value**.

Our founder Dr. Leon Tang is an established BD and R&D expert

Education & Work Experiences




Memorial Sloan Kettering
Cancer Center



Expert in BD, Community building, and R&D

1. **An accomplished BD executive** in biotech who has contributed to or closed deals with total value of **\$3.0+ billion**.
2. **A super-connector** with **9,500+ LinkedIn followers** who come from all sectors of the healthcare industry primarily in the North America, APAC, and Europe.
3. **An accomplished scientist with 50 publications**, including 6 senior-author Nature Reviews Drug Discovery, 1 Lancet Oncology, 1 Nature BME, 1 Science Translational Medicine, 3 Nature Communications (1 first-author), 1 first-author Science Advances, 3 PNAS (2 first-author), etc. **with H-index of 35 and 6.1K citations.**

A high-quality global network



7,200+ LinkedIn connections (as of Q1 2026)

- Decision maker
(VP+ in MNC, C-suite in biotech, and equivalents)
- Mid-level
(AD-ED of MNC and biotech, and equivalents)
- Entry-level
(Up to senior scientist or senior associate)
- Others
(Academia, media, NGOs, etc.)



Agenda

- **The current “China for Global” boom is driven by China’s fast & cost-effective R&D**
- Pharmaceutical licensing and R&D collaboration are two common strategies to utilize the rise of China biotech
- We have unparalleled access to China biotechs and global biopharmas via our vast network


China biotech could move 3 times faster in fast-follow preclinical R&D



Discovery: 50-70% acceleration from target to IND for fast-following small molecules
Average time from target nomination to PCC and IND submission, months




Key drivers




- 1 Streamlined discovery workflows
- 2 Closer CRO integration
- 3 Hyper-focus on delivery

China runs clinical trials faster and cheaper than others




Cui Cui, Jefferies Research, July 2025




Tatake, The State of Biopharmaceutical Industry 2025, GlobalData

China biotech leads in the global R&D activities

China Surpasses US in Innovative Drug Development




Global Clinical Trials Rise in the Past Decade as China Takes the Lead



Source: [PharmCube](#), Published on 2026-01-21

Western companies are sourcing early-stage innovations from China


48 Deals Brought in \$8.4 Billion Upfront in 2024



[Tang et al, Nature Reviews Drug Discovery, April 2025.](#)

Only **M&A and licensing deals** with disclosed upfront payment were included. Pre-money equity of newco deals and near-term milestone, if disclosed, were included in the upfront payment calculation, while and long-term milestone payments were excluded.

China is the largest source of licensing deals



Source: [PharmCube, Published on 2026-01-21](#)

In 2025, China-originated licensing deals contributed to **49%** of the value of all global BD&L deals, followed by 27% from the US, 16% from the EU, and 7% from all other countries.



Agenda

- The current “China for Global” boom is driven by China’s fast & cost-effective R&D
- **Pharmaceutical licensing and R&D collaboration are two common strategies to utilize the rise of China biotech**
- We have unparalleled access to China biotechs and global biopharmas via our vast network

China biotech is rewriting the global pharmaceutical R&D playbook

First-in-human data from China led to a \$1-billion M&A

AstraZeneca goes in vivo, penning \$1B deal for Belgian off-the-shelf cell therapy biotech

By James Waldron · Mar 17, 2025 7:40am

[AstraZeneca](#) [mergers and acquisitions](#) [Cell & Gene Therapy](#) [CAR-T](#)



Chinese-asset enabled a \$2.2-billion acquisition by GSK

GSK pays \$2.2B to buy Rapt for its phase 2-stage food allergy challenger to Xolair

By James Waldron · Jan 20, 2026 4:37am

[GSK](#) [Rapt Therapeutics](#) [mergers and acquisitions](#) [Xolair](#)



\$18.5-billion licensing deal of 8 preclinical obesity assets

AstraZeneca returns to China's CSPC for \$18.5B obesity deal

By James Waldron · Jan 30, 2026 4:50am


[AstraZeneca](#) [CSPC Pharmaceutical](#) [Licensing deals](#) [Obesity](#)



High-quality innovations & data drive meaningful BD or M&A deals with global biopharma/biotech

Newcos backed by Asian assets have made impressive returns

Leverage **Chinese assets** to create NewCo



Source: [BioCentury](#)

Summit Therapeutics rise on the back of a **Chinese asset**

THE WALL STREET JOURNAL.

TECHNOLOGY | BIOTECH | HEARD ON THE STREET [Follow](#)

How a Surfer Who Never Finished College Became a Biotech Billionaire

Bob Duggan's success shows you don't need a Ph.D., or even a college education, to make money in the complex world of biotechnology

By [David Wainer](#) [Follow](#)

Sept. 23, 2024 7:00 am ET

STAT Reporting from the frontiers of health and medicine

Newsletters My Account **STAT+**

Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT Summit

Ads by Google

[Send feedback](#) [Why this ad? >](#)

STAT+ | EXCLUSIVE

The little-known Chinese biotech whose cancer drug beat Keytruda has global ambitions

Akeso, which discovered the immunotherapy, wants to be seen as 'not just a China story'

Source: [The Wall Street Journal](#); [STAT News](#)

Two Successful Strategies to Leverage China Biotech

East-to-West assets licensing via M&A, BD, or newco deals

**China-originated
innovative
assets**

+

Global clinical
development capability

+

Fundraising, BD&L, and
M&A in the global market

=

**Significant
success**

West-to-East “Reverse Newco” to speed up Western assets’ development

**West-originated
innovative
assets**

+

China’s fast & cost-
effective R&D

+

Fundraising, BD&L, and
M&A in global market

=

**Significant
success**




Agenda

- The current “China for Global” boom is driven by China’s fast & cost-effective R&D
- Pharmaceutical licensing and R&D collaboration are two common strategies to utilize the rise of China biotech
- **We have unparalleled access to China biotechs and global biopharmas via our vast network**

Dr. Leon 'Jun' Tang is well established R&D and BD expert

2018 Nobel Prize for Physiology and Medicine – Dr. Tasuku Honjo



Dr. Tang's first-author paper was cited as a landmark paper during [Nobel Lecture by Dr. Honjo](#) during his 2018 Nobel Speech.

Founder of BioVerse webinar that has generated ~380,000 unique views



Creator and host of [BioVerse webinar](#) co-produced by [InScienceWeTrust Community](#), SAPA-GP, and BioSpark

Recognized China expert by leading news media

- 2025 *Nature Reviews Drug Discovery* article on [China-to-West deals](#).
- 2025 *Fierce Pharma* article on the [Novo vs KBP \\$1.3 Billion Dispute](#).
- 2025 China News Weekly 《中国新闻周刊》: [创新药出海大爆发](#)
- 2024 *LinkedIn Self-Publication* on [China for Global T-cell engager deals](#)
- 2024 *Fierce Biotech* article on [how geopolitics may hinder "China for Global" movement](#).
- 2024 *Caixin Global* cover story [article on the recent Chinese companies' out-licensing setbacks](#)

Leverage leading professional platforms to connect with decision-makers in the US, Europe, and East Asia

Featured China expert for US biotech investors



After being featured in [a 2024 KOL call](#), Leon was invited to join a [China panel in 2025 at Cantor Global Healthcare Conference in 2025](#).

Featured speaker in Europe-based podcasts



[Cures & Capital PODCAST in 2025](#)



[China Health Pulse, March 2026](#)

Featured BD&L expert in a China-based show



张蕊会客厅 – [A round table discussion on the impact of Trump draft EO, 100% tariff, and MFN on China biotech/biopharma](#)

Dr. Tang is the co-founder of Asian biotech nonprofit InScienceWeTrust Community

BioVerse webinar has **13,000+** live attendees per episode




BioVerse webinar is co-produced by ISWT Community, SAPA-GP, and BioSpark Group, three US-based nonprofits.

Our webinars attract on average **13,000+** live attendees per episode, and about 50% of our attendees hold mid to senior positions in their companies.

United States and China account for 80% of our audience, while the remaining audience come from all major biotech hubs around the world.

A weekly newsletter has **~6,000** subscribers with **70%** open rate

Asian Biotechies In A Bar



Visit ISWT Community website

4,000+ active members from **11** focus groups & LinkedIn

R&D (full) focuses on R&D and VC in biotech – 500 members

BusinessOne (full) and **BusinessTwo** focus on investment, BD, CDMO, law, and consulting

Oncology focuses on cancer drug development & research

CGT focuses on Cell & Gene Therapy

ChronicDisease focuses on chronic diseases

Boston Chapter focuses on executive members in the great Boston area

Great New York Chapter focuses on executive members in NY, NJ, CT, and PA

West Coast Chapter focuses on executive members in California, Oregon, and Washington.

Shanghai Chapter focuses on biotech and biopharma executives in Yangtze River Delta

Europe Chapter on WhatsApp serves members in Europe

We help Western biotechs generate proof-of-concept clinical data in China at a lightening speed and low cost



+



Opportunities

- **Abundant clinical resources:**
Large patient pools, world-class hospitals, and experienced bilingual PIs
- **Lower cost, faster execution:**
Often “half the cost and twice the speed”
- **Regulatory flexibility:**
Quasi-dual-track pathways enabling early proof-of-concept studies
- **Proven local advantage:**
China biotechs often achieve faster, more cost-effective early-stage development than U.S./EU peers

Challenges

- **Local competition & regulatory risk:**
Securing priority access to clinical resource while mitigating “foreigner” risk
- **Inconsistent quality:**
Variable process and quality standards across sites and PIs
- **IP & data protection:**
Potential exposure of proprietary technologies and sensitive data
- **Cross-border Collaboration:**
Coordination across regulatory, operational, and cultural boundaries between China-based teams and Western sponsors

More about [Mianus Accelerator](#)

Our partners and collaborators together provide the best access to innovations and R&D capabilities in Asian biotech space



[A clinical development accelerator](#)



[A global talents solution provider](#)



ISWT BioAdvisory

Travel Together, Go The Distance

<https://www.iswtb.com>



We have advised 30+ clients in the global biotech industry

Who are our clients?

- 24 biotech companies, 5 investment firms, 1 CRO, and 1 Fortune 500 company.
- 18 companies from North America, 12 from Greater China, and 1 from Europe.
- Our key capabilities:
 - East-to-West asset licensing.
 - West-to-East “reverse newco” or R&D partnership.
 - First-in-human trials, especially investigator-initiated trials (IIT), in China.

Representative projects

The logo for VelaVigo, featuring the word "Vela" in blue and "Vigo" in blue with a stylized orange and yellow dot pattern.

Assisted the out-licensing deal with Avenzo worth \$750 million, and the subsequent Pre-A financing of \$50 million in 2024

A public US biotech company

Advised the company to initiate investigator-initiated trial (IIT) with their first-in-class allogeneic cell therapy in China

A private Canadian biotech company

Advising the company to leverage China R&D efficiency via asset licensing and R&D collaboration in chronic disease space

A leading healthcare specialist fund

Leading the BD&L of Chinese asset for a newco backed by a leading healthcare specialist fund with \$15+ billion AUM.

Thank You!

Contact & Follow Us

Email: leon.tang@iswtb.com

WeChat: LeonTangBiotech

Visit our website: www.iswtb.com

Follow us on [LinkedIn here.](#)

[Book a meeting with us!](#)



WeChat



LinkedIn

Travel Together, Go The Distance